Compare BRFH & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | CNSY |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 20.6M |
| IPO Year | 2010 | 2016 |
| Metric | BRFH | CNSY |
|---|---|---|
| Price | $1.13 | $2.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 24.6K | ★ 62.3K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.53 | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | $211,467.00 | ★ $5,213,000.00 |
| Revenue This Year | $115.22 | N/A |
| Revenue Next Year | $16.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 92.09 | N/A |
| 52 Week Low | $1.09 | $2.00 |
| 52 Week High | $4.25 | $4.03 |
| Indicator | BRFH | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 29.87 | 20.74 |
| Support Level | N/A | N/A |
| Resistance Level | $1.45 | $3.28 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 5.56 | 7.34 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.